Form 4 for ADPT Adaptive Biotechnologies Corp
Accepted 2026-04-21 18:07:41 ET · period of report 2026-04-17 · accession 0001780664-26-000028 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-04-21 18:07 | 2026-04-17+ | ADPT | RUBINSTEIN JULIE | Pres, COO | M - OptEx | $9.24 | +56.0K | 426.1K | +15% | +$517.9K |
| DMT | 2026-04-21 18:07 | 2026-04-17+ | ADPT | RUBINSTEIN JULIE | Pres, COO | S - Sale+OE | $14.60 | -69.1K | 395.1K | -15% | -$1.01M |
| DMT | 2026-04-21 18:07 | 2026-04-17+ | ADPT | RUBINSTEIN JULIE | Pres, COO | M - OptEx | $0.00 | -56.0K | 379.8K | -13% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-17 | M | A | 14,722 | $8.46 | 422,882 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. |
| 2 | Common | Common Stock | 2026-04-17 | S | D | 19,060 | $14.57 | 403,822 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. (F2) The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.38 to $14.91, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| 3 | Common | Common Stock | 2026-04-20 | M | A | 14,722 | $8.46 | 418,544 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. |
| 4 | Common | Common Stock | 2026-04-20 | S | D | 19,060 | $14.55 | 399,484 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. (F3) The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.14 to $14.82, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| 5 | Common | Common Stock | 2026-04-21 | M | A | 14,722 | $8.46 | 414,206 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. |
| 6 | Common | Common Stock | 2026-04-21 | M | A | 11,881 | $12.14 | 426,087 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. |
| 7 | Common | Common Stock | 2026-04-21 | S | D | 30,941 | $14.66 | 395,146 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. (F4) The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.18 to $15.13, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| 8 | Derivative | Stock Option (right to buy) | 2026-04-17 | M | D | 14,722 | $0.00 | 134,048 | D | $8.46 · — to 2033-03-06 | 14,722 Common Stock | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. (F5) The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
| 9 | Derivative | Stock Option (right to buy) | 2026-04-20 | M | D | 14,722 | $0.00 | 119,326 | D | $8.46 · — to 2033-03-06 | 14,722 Common Stock | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. (F5) The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
| 10 | Derivative | Stock Option (right to buy) | 2026-04-21 | M | D | 14,722 | $0.00 | 104,604 | D | $8.46 · — to 2033-03-06 | 14,722 Common Stock | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. (F5) The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
| 11 | Derivative | Stock Option (right to buy) | 2026-04-21 | M | D | 11,881 | $0.00 | 379,777 | D | $12.14 · — to 2032-03-04 | 11,881 Common Stock | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. (F6) The option is fully vested and exercisable. |